Safety of coagulation factor concentrates

Haemophilia

Volumn 4, Issue 4, 1998, Pages 393-401

  Teitel, J M ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Clotting factor concentrates; Hepatitis B virus; Hepatitis C virus; HIV; Viral inactivation; Viral safety

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE; NUCLEIC ACID; PRION PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ACTIVE IMMUNIZATION; ANTIBODY DETECTION; ANTIGEN DETECTION; CONFERENCE PAPER; CONTAMINATION; DISEASE TRANSMISSION; DONOR; DRUG PURITY; HUMAN; IMMUNOGENICITY; MAMMAL CELL; PRION DISEASE; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; RISK; SAFETY; SCREENING; VIRUS LOAD;

EID: 0031876274     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.440393.x     Document Type: Conference Paper

References (61)

1. Minot GR, Taylor FHL. Hemophilia: the clinical use of antihemophilic globulin. Ann Intern Med 1947; 26: 363-7.
2. Macfarlane RG, Biggs R, Bidwell E. Bovine antihaemophilic globulin in the treatment of haemophilia. Lancet 1954; 1: 1316-9.
3. Didisheim P, Loeb J, Blatrix C, Soulier JP. Preparation of human plasma fraction rich in prothrombin, proconvertin, stuart factor and PTC and a study of its activity and toxicity in rabbits and man. J Lab Clin Med 1959; 53: 322-30.
4. Pool JG, Shannon AE. Production of high potency concentrates of antihemophilic globulin in a closed bag system: assay in vitro and in vivo. N Engl J Med 1965; 273: 1443-7.
5. Rizza CR. Management of patients with inherited coagulation defects. In: Bloom AL, Thomas DP, eds. Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1981; 371-88.
6. Orringer EP, Koury MJ, Blatt PM, Roberts HR. Hemolysis caused by factor VIII concentrates. Arch Intern Med 1976; 136: 1018-20.
7. Blatt PM, Lundblad RL, Kingdon HS, McLean G, Roberts HR. Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med 1974; 81: 766-70.
8. De Biasi R, Rocino A, Miraglia E, Mastrullo L, Quirino AA. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virusinfected hemophiliacs: A randomized, prospective, two-year comparison with an intermediate purity concentrate. Blood 1991; 78: 1919-22.
9. Seremetis SV, Aledort LM, Bergman GE, Bona R, Bray G, Brettler D, et al. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptomfree HIV-seropositive haemophiliacs: Effects on immune status. Lancet 1993; 342: 700-3.
10. Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-7.
11. Shopnick RI, Kazemi M, Brettler DB, Buckwalter C, Yang L, Bray G, et al. Anaphylaxis after treatment with recombinant factor VIII. Transfusion 1996; 36: 358-61.
12. Newton-Nash DK, Tollerud D, Guevarra L, Gill JC. Interferon-gamma secretion defects in haemophilia A patients receiving highly purified plasma-derived or recombinant factor VIII. Br J Haematol 1996; 95: 554-60.
13. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-54.
14. Yee TT, Williams MD, Hill FGH, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost 1997; 78: 1027-9.
15. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996; 97: 1382-8.
16. Rosendaal FR, Nieuwenhuis HK, Van den Berg HM, Heijboer H, Mauser-Bunschoten EP, Van der Meer J, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993; 81: 2180-6.
17. Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, et al. Factor VIII inhibitors in previously treated haemophilia a patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
18. Barrowcliffe TW, Kemball-Cook G, Tubbs JE. Inhibitor development and activated factor VIII in concentrates. Thromb Haemost 1993; 70: 1065-6.
19. Josic DJ, Stadler M, Buchacher A, et al. Degradation products of factor VIII which can lead to increased immunogenicity. Thromb Haemost 1997; 77(Suppl): 576.
20. Lollar P, Parker ET, Fay PJ. Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem 1992; 267: 23652-7.
21. Richards EM, Makris MM, Cooper P, Preston FE. In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol 1997; 96: 293-7.
22. Schulman S, Johnsson H, Lindmarker P. Thrombotic complications after substitution with a FVII concentrate. Thromb Haemost 1991; 66: 619.
23. Stein SF, Duncan A, Cutler D, Glazer S. Disseminated intravascular coagulation in a hemophiliac treated with recombinant factor VIIa. Blood 1990; 76 (Suppl 1): 438a.
24. Gumming AM, Armstrong JG, Burn AM, Wensley RT. Co-existence of von Willebrand's disease and haemophilia A. Clin Lab Haematol 1992; 14: 91-2.
25. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
26. Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med 1994; 120: 1-7.
27. Lawlor E, Johnson Z, Thornton L, Temperley I. Investigation of an outbreak of hepatitis A in Irish haemophilia A patients. Vox Sang 1994; 67 (Suppl. 1): 18-20.
28. Soucie JM, Robertson BH, Bell BP, et al. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Blood 1997; 90 (Suppl 1): 408a.
29. Lawlor E, Graham S, Davidson F, Yap PL, Cunningham C, Daly H, et al. Hepatitis A transmission by factor IX concentrates. Vox Sang 1996; 71: 126-8.
30. Anonymous. Hepatitis A among persons with hemophilia who received clotting factor concentrate - United States, September-December 1995. MMWR Morb Mortal Wkly Rep 1996; 45: 29-32.
31. Sheng L, Soumillion A, Peerlinck K, Verslype C, Lin L, Van Pelt J, et al. Hepatitis G viral RNA in serum and in peripheral blood mononuclear cells and its relation to HCV-RNA in patients with clotting disorders. Thromb Haemost 1997; 77: 868-72.
32. Jarvis LM, Davidson F, Hanley JP, Yap PL, Ludlam CA, Simmonds P. Infection with hepatitis G virus among recipients of plasma products. Lancet 1996; 348: 1352-5.
33. Miyakawa Y, Mayumi M. Hepatitis G virus - A true hepatitis virus or an accidental tourist? N Engl J Med 1997; 336: 795-6.
34. Giangrande PLF. Viral pharmacovigilance studied on inhibitor patients receiving porcine factor VIII. Porcine FVIII Developments Towards 2000. San Diego, CA; 1997 (symposium).
35. Manuelidis L. The dimensions of Creutzfeldt-Jakob disease. Transfusion 1994; 34: 915-28.
36. Créange A, Gray F, Cesaro P, Degos JD. Pooled plasma derivatives and Creutzfeldt-Jakob disease. Lancet 1996; 347: 482.
37. Kuroda Y, Gibbs CJ, Jr., Amyx HL, Gajdusek DC. Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 1983; 41: 154-61.
38. Rohwer R. Potential infectivity of blood from subjects with TSE (humans and experimental animals) and effects of fractionating on infectivity: experimental studies. Meeting of the Transmisible Spongiform Encephalopathies Advisory Committee. Bethesda, MD; 1997.
39. Taswell HF. Competition in blood services. In: Clark GM, ed. Directed, Paid, and Self Donors, Part III. Arlington, VA: AABB, 1987; 137-48.
40. Polesky HF. Improving the safety of transfusion therapy. Clin Lab Med 1996; 16: 975-88.
41. Finlayson JS, Tankersley DL. Anti-HCV screening and plasma fractionation: the case against. Lancet 1990; 335: 1274.
42. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334: 1685-90.
43. Hoofnagle JH. Posttransfusion hepatitis B. Transfusion 1990; 30: 384-6.
44. Thiers V, Nakajima E, Kremsdorf D, Mack D, Schellekens H, Driss F, et al. Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet 1988; 2: 1273-6.
45. Ferguson M, Minor PD, Garrett AJ, Page M, Thorpe R, Barrowcliffe T. Testing plasma pools for markers of viral contamination: the UK experience. Vox Sang 1996; 71: 21-6.
46. Ulrich PP, Romeo JM, Lane PK, Kelly I, Daniel LJ, Vyas GN. Detection, semiquantitation, and genetic variation in hepatitis C virus sequences amplified from the plasma of blood donors with elevated alanine aminotransferase. J Clin Invest 1990; 86: 1609-14.
47. Coutlee F, Viscidi RP, Saint-Antoine P, Kessous A, Yolken RH. The polymerase chain reaction: a new tool for the understanding and diagnosis of HIV-1 infection at the molecular level. Mol Cell Probes 1991; 5: 241-59.
48. Kleinman SH, Busch MP, Stramer SL. First year experience with HIV p24 antigen (AG) testing: Ag indeterminate donors are not infected with HIV. Blood 1997; 90 (Suppl 1): 408a.
49. Vyas GN, Yang G, Murphy EL. Transfusion-related transmissible diseases: detection by polymerase chain reaction-amplified genes of the microbial agents. Transfusion Med Rev 1994; 8: 253-66.
50. Eble BE, Busch MP, Khayam-Bashi H, Nason MA, Samson S, Vyas GN. Resolution of infection status of human immunodeficiency virus (HIV) - seroindeterminate donors and high-risk seronegative individuals with polymerase chain reaction and virus culture: absence of persistent silent HIV type 1 infection in a high-prevalence area. Transfusion 1992; 32: 503-8.
51. Hoffer L, Schwinn H, Biesert L, Josic D. Improved virus safety and purity of a chromatographically produced Factor IX concentrate by nanofiltration. J Chromatogr B Biomed Appl 1995; 669: 187-96.
52. Suomela H. Inactivation of viruses in blood and plasma products. Transfusion Med Rev 1993; 7: 42-57.
53. Mannucci PM, Schimpf K, Abe T, Aledort LM, Anderle K, Brettler DB, et al. Low risk of viral infection after administration of vapor-heated factor VIII concentrate. Transfusion 1992; 32: 134-8.
54. Winkelman L, Feldman PA, Evans DR. Severe heat treatment of lyophilised coagulation factors. Curr Stud Hematol Blood Transfus 1989; 56: 55-69.
55. Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 1985; 25: 516-22.
56. Smith MP, Rice KM, Savidge GF. Successful clinical use of a plasma-derived, dual virus inactivated factor VIII concentrate incorporating solvent-detergent and dry heat treatment. Thromb Haemost 1997; 77: 406-7.
57. Hart HF, Hart WG, Crossley J, Perrie A, Wood DJ, John A, et al. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates. Vox Sang 1994; 67: 345-50.
58. Robinson S. A double virus-inactivated factor VIII preparation: Validation and biochemical characteristics. Vox Sang, 1994; 67 (Suppl. 1): 67-8.
59. Shapiro AD, Ragni MV, Lusher JM, Culbert S, Koerper MA, Bergman GE, et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thromb Haemost 1996; 75: 30-5.
60. Mohr H, Lambrecht B, Selz A. Photodynamic virus inactivation of blood components. Immunological Investigations 1995; 24: 73-85.
61. Chin S, Williams B, Gottlieb P, Margolis-Nunno H, Ben-Hur E, Hamman J, et al. Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: Protection of proteins by antioxidants. Blood 1995; 86: 4331-6.